Name: UMIN ID:
Unique ID issued by UMIN | UMIN000015123 |
---|---|
Receipt number | R000017592 |
Scientific Title | Phase II trial of S-1 plus Cetuximab combination therapy in patients inappropriate for platinum-based therapy with recurrent/metastatic squamous cell carcinoma of the head and neck |
Date of disclosure of the study information | 2014/09/11 |
Last modified on | 2019/10/06 00:53:04 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2014/09/11 16:51:12 | ||
2 | Update | 2015/04/14 20:48:09 | Recruitment status |
|
3 | Update | 2015/09/11 19:20:18 | Key inclusion criteria Key inclusion criteria |
|
4 | Update | 2017/03/28 09:02:01 | Name of primary person or sponsor Organization |
|
5 | Update | 2018/04/19 20:24:08 | Key inclusion criteria Key inclusion criteria |
|
6 | Update | 2019/05/01 14:50:24 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Organization Organization Division name Zip code Last name of contact person Last name of contact person Organization Organization Division name Zip code Organization Organization Division name Tel1 Organization Organization Address Address Tel |
|
7 | Update | 2019/05/01 15:13:16 | Recruitment status Date of IRB Last follow-up date |
|
8 | Update | 2019/05/01 15:16:42 | Number of participants that the trial has enrolled |
|
9 | Update | 2019/10/06 00:53:04 | Recruitment status |